SPRING, Texas--(BUSINESS WIRE)-- Exxon Mobil Corporation (NYSE: XOM) today announced it has closed its acquisition of Pioneer Natural Resources Company (NYSE: PXD). The merger of ExxonMobil and Pioneer creates an Unconventional business with the largest, high-return development potential in the Permian Basin. The combined company’s more than 1.4 million net acres in the Delaware and Midland basins have an estimated 16 billion barrels of oil equivalent resource. ExxonMobil’s Permian production volume will more than double to 1.3 million barrels of oil equivalent per day (MOEBD), based on 2023...
A director at Alphatec Holdings Inc sold 37,500 shares at 12.820USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SPRING, Texas--(BUSINESS WIRE)-- Exxon Mobil Corporation (NYSE:XOM): Results Summary Dollars in millions (except per share data) 1Q24 4Q23 Change vs 4Q23 1Q23 Change vs 1Q23 Earnings (U.S. GAAP) 8,220 7,630 +590 11,430 -3,210 Earnings Excluding Identified Items (non-GAAP) 8,220 9,963 -1,743 11,618 -3,398 ...
A director at Biohaven Ltd bought 25,503 shares at 39.179USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Ultralife Corporation Reports First Quarter Results NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of ...
Merus gibt Annahme von Abstracts zur Präsentation auf der ASCO-Jahrestagung 2024 bekannt Petosemtamab in Kombination mit Pembrolizumab als 1L bei HNSCC – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-145 als Monotherapie oder in Kombination mit Pembrolizumab bei soliden Tumoren – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-129 bei NSCLC mit c-MET-Exon-14-Skipping-Mutationen – erste vorläufige klinische Daten für eine Posterpräsentation ausgewählt UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, April 25, 2...
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO Pétosemtamab en association avec le pembrolizumab en traitement de première intention du carcinome épidermoïde de la tête et du cou : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-145 en monothérapie ou en association avec le pembrolizumab dans les tumeurs solides : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-129 dans le cancer bronchique non à petites cellules avec mutations conduisant à un saut de ...
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Me...
SPRING, Texas--(BUSINESS WIRE)-- Exxon Mobil Corporation (NYSE: XOM) announced today that it has applied to the Alberta Securities Commission (ASC), as principal regulator, and the Ontario Securities Commission (OSC) for a joint order (the Order Sought) to cease to be a reporting issuer in each of the provinces of Canada. ExxonMobil is not a reporting issuer in any other Canadian jurisdiction. If the Order Sought is granted by the ASC and the OSC, ExxonMobil will cease to be a reporting issuer in any jurisdiction in Canada. Notwithstanding a decision that ExxonMobil is not a reporting issu...
SPRING, Texas--(BUSINESS WIRE)-- Exxon Mobil Corporation (NYSE: XOM) will release its first quarter 2024 financial results on Friday, April 26, 2024. The company will issue a press release via Business Wire that will be available at 5:30 a.m. CT at . Chairman and Chief Executive Officer Darren Woods and Senior Vice President and Chief Financial Officer Kathy Mikells will review the results during a live conference call at 7:30 a.m. CT. The presentation will be accessible via or by calling (888) 277-7112 (Toll-free) or (786)-789-4836 (Local). Please reference passcode 2098885 to join the cal...
SPRING, Texas--(BUSINESS WIRE)-- ExxonMobil has made a final investment decision for the Whiptail development offshore Guyana, after receiving the required government and regulatory approvals. Whiptail, the sixth project on the Stabroek block, is expected to add approximately 250,000 barrels of daily capacity by the end of 2027. “Our sixth multi-billion-dollar project in Guyana will bring the country’s production capacity to approximately 1.3 million barrels per day,” said Liam Mallon, president of ExxonMobil Upstream Company. “Our unrivaled success in developing the Guyana resource at indus...
Ultralife Corporation to Report First Quarter Results on April 25, 2024 NEWARK, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its first quarter results for the period ended March 31, 2024 before the market opens on Thursday, April 25, 2024. Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we re...
CenterPoint Energy, Inc. to Host Webcast of First Quarter 2024 Earnings Conference Call Houston, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Date: April 30, 2024 Time: 7:00 a.m. Central time or 8:00 a.m. Eastern time Listen via internet: Click "Investors", and click the link "CenterPoint Energy, Inc. First Quarter 2024 Earnings Conference Call" As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power gen...
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Me...
Merus stellt auf der AACR-Jahrestagung 2024 präklinische Daten als Beleg für die Wirksamkeit von Zeno in Krebsmodellen mit hoher NRG1-Expression vor UTRECHT, Niederlande, und CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) („Merus“, „das Unternehmen“, „wir“ oder „unser“), ein in der klinischer Phase tätiges Unternehmen im Bereich der Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, gab heute die Vorstellung von präklinischen Daten zu Zenocutuzumab (Zeno) in Krebsmodellen mit hoher Neuregulin 1 (NRG1)-Expres...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.